Wednesday, August 31, 2011

Basic Principles of Low-Level Laser Therapy and Clinical Applications for Pain Relief chiropractic http://ping.fm/Yvl5j

Theralase Technologies Inc. Announces Q2 Financials - Earnings call Sept 1 at 8:30am


Toronto, Ontario – August 30, 2011 Theralase Technologies Inc. (TSX‐V: TLT) announces its second quarter 2011 financials.
Revenue remained fairly constant year over year with total revenue for the three month period ending June 30, 2011 at $688,606, compared to $640,270 for the same period in 2010, an increase of 7.5%.
Selling expenses increased for the three month period ending June 30, 2011 to $327,216, compared to $165,432 for the same period the previous year an increase of 98%. The increase is primarily due to increases in the sales and marketing costs associated with the new Territory Sales Managers hired for the US market expansion.
Administrative expenses increased to $319,972 for the three month period ending June 30, 2011 compared to $311,707 for the same period the previous year, an increase of 2.7% as a result of increased expenditures on administrative staff.
Research and development costs increased to $176,623 for the three month period ending June 30, 2011 compared to $161,299 for the same period in 2010, a 9.5% increase. The increase is primarily due to the development costs associated with the patented TLC-2000 biofeedback therapeutic laser system, scheduled to be commercially launched Q1 2012 and costs associated with the research and development of Theralase’s patented Photo Dynamic Compounds (PDCs) being developed for cancer, virus and bacteria destruction. In order to capitalize on this research for sterilization in the food processing industries, Theralase has entered into an applied research partnership with George Brown College and is considering other strategic alliances.
Roger Dumoulin‐White, President and CEO of Theralase Technologies Inc. stated, “The net loss for the three month period ended June 30, 2011 was $357,262 which included $20,597 of non-cash expenses (amortization, stock-based compensation expense, foreign exchange gain/loss and lease inducements). The company expenses the future product development costs of the patented TLC‐2000 biofeedback therapeutic laser system and TLC‐3000 Photo Dynamic Compound technology from existing TLC‐1000 therapeutic laser product sales, resulting in the overall net loss. The investment in our future will secure our position as an international leader in medical laser technology both in the therapeutic tissue healing space as well as the tissue destruction space for decades to come.”
During the quarter, Theralase announced the appointment of Dr. James R. Andrews as Chairman to its Medical and Scientific Advisory Board. Further appointments include senior medical orthopaedic practitioners and healthcare specialists from the renowned American Sports Medicine Institute (ASMI) and Alabama Sports Medicine & Orthopaedic Center (ASMOC) located in Birmingham, Alabama. ASMOC, founded by Dr. Andrews, is a specialized North American facility widely recognized throughout the world for the treatment of a full range of orthopaedic sports injuries. ASMI is a world renowned sports medicine research and education foundation. Joining Dr. Andrews as Advisory Board appointees are medical and physiotherapy specialists from ASMI, including: Dr. Lyle Cain, Dr. Jeffrey Dugas, Kevin Wilk, DPT and Lanier Johnson. They are an elite and influential team of professionals who are able to help guide Theralase in the expansion of its world class therapeutic laser technology into the US medical market.
Theralase is preparing for significant growth in the 2nd half of 2011 and in 2012 as the Company expands its sales and marketing efforts in the US and internationally and prepares for the launch of its patented TLC‐2000 biofeedback therapeutic laser in Q1 2012.
The complete consolidated financial statements and MD&A for the three and six months ending June 30, 2011 can be found at www.theralase.com and www.sedar.com.
There is an earnings conference call scheduled for September 1st, 2011 at 8:30am ET. The call in number is 1-866-440-8936, the conference ID is 8791351#. The call will be hosted by Roger Dumoulin-White, President & CEO of Theralase Technologies Inc.
About Theralase Technologies Inc.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses, as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information
Roger Dumoulin-White                                                                                
President & CEO,                            
416-447-8455 ext. 225                                   

Greg Bewsh
Director of Investor Relations,
416-447-8455 ext. 262

Monday, August 29, 2011

Cold Laser Therapy and Treatments - A Chiropractic View http://ping.fm/mKGNd

Cold Laser Therapy and Treatments - A Chiropractic View


Cold Laser Treatments

The first time I saw star wars, I was six years old. I remember my friend going on and on about Darth Vader and C3PO. He was fascinated by these characters. I on the other hand was fascinated by the light saber. I thought it was the coolest thing that I had ever cast my young eyes on. The light saber was a laser sword that could cut through almost any substance, and could only be deflected by another light saber.

It was the first laser of any kind that I can remember, and I fought many mock light saber duels with my fellow star wars jedi wannabes. I thought a laser of any kind was a dangerous and powerful weapon and not until years later, while visiting the dentist, did I realize it's healing potential.

Low Laser Light therapy or cold laser therapy is a treatment modality that I have been investigating and interested in for many years. Many of my colleagues have reported great results with these devices that it sparked my interest. The health benefits of the low level laser include:

  • Reduces inflammation
  • Relieves both acute and chronic pain
  • Speeds up tissue repair
  • Increases the quality and tensile strength of the tissue
  • Increases blood supply
  • Promotes faster wound healing and clot formation
  • Stimulates the immune system
  • Stimulates nerve function
  • Develops muscle tissue and collagen
  • Helps generate new and healthy cells and tissue
  • Aids in neuroplasticity
  • Can be used on acupuncture points
  • Can be used for desensitization to food intolerances

These are only some of the possible applications and outcomes.

Biological light receptors in tissue are called chromophores. Chromophores have been researched to have a maximum therapeutic activation at 660 nm and 905 nm wavelength. It is the activation of these chromophores that causes many healing biochemical reactions. For example as soon as a chromophore is activated the oxygen carrying capacity of blood in the region being treated increases by three times, which aids in the healing process. It is the collimation, coherency and polarization of the laser light that allows the light to penetrate the skin and activate the chromophore.

Some benefits of using low level laser therapy is the device can be used on a patient with a comfortable distance from the wound and tissue being treated, It can be administered through natural fiber clothing, eye protection is not necessary for the doctor or the patient, the patient doesn't feel heat and has very little sensation, and it takes very little time to treat an area.

Since I have been using low level laser therapy in my practice and I have had great results with numerous patients. This week a patient came into my practice after being in a minor car accident. Her neck was in spasm and she could barely turn her head to the left. I pushed on her trapezius and levator scapulae muscles and she responded with an "Ouch that is really tender".

I performed sweeping movements with the laser for about 90 seconds on both of these muscles. When I touched these muscles after using the low level laser, she indicated that the tenderness had gotten better and had about 60% less pain in these muscles. After the laser treatment I performed a gentle spinal manipulation on her neck and she said that the adjustment was fluid, not painful, and she felt significantly better.

Another patient came into the practice with tennis elbow (pain at the lateral side of the elbow). I used the low level laser and he reported a significant decrease in pain after 6 sessions. There is a great article that discusses low level laser treatment of tendinopathy in the journal Photomed Laser Surg, 2010.

Many patients have discovered what foods or allergens are a problem for their bodies through the nutrition response testing technique. I have recently introduced a desensitization technique that uses laser acupuncture to help the body to become tolerant to these foods again.

After using the laser on the master points and the patient complying with three weeks of abstaining completely from these foods, many have been able to tolerate these foods again. Using the laser on these points acts as a kind of rewiring, so the body doesn't react in the same way and responds better to these foods.

As we continue to discover and appreciate the benefits of light as a therapy, may there be increased light in all of your lives!

Healthfully yours,

Dr. Louis Granirer

For more information please call 1-866-843-5273 or visit www.theralase.com

Friday, August 26, 2011

Laser Therapy Shines as an Alternative Complementary Treatment for Pain Management and Healing

Written by Jesse C. Ploessl, DCReviewed by Ron Grassi, DC MS ACFEI


Looking for a unique treatment that can help your body heal from chronic injuries and relieve pain? Low level laser therapy (LLLT), or "cold laser" is changing the way medical doctors, chiropractors, physical therapists, and other health care professionals are helping individuals heal from injuries and chronic disease and improve their quality of life.
How LLLT Works 
Low level laser therapy traces its history back to the early 1960's when researchers discovered that laser light could stimulate a response at the cellular level of tissues in the body, resulting in increased energy levels (ATP, adenosine triphosphate). This increase in energy enables the body's cells to metabolize at a higher rate and speeds its natural ability to heal. In short, the body converts the laser light into a form of energy that it can use (biochemical energy) to repair itself and function at a higher efficiency level. This process is similar to the human body using the sun's energy to manufacture Vitamin D.
FDA Approved 
Researchers have since experimented over the decades to find out which intensities and wavelengths of light work best to promote healing in the body. Laser therapy has been successfully utilized in Europe, Asia, and Canada for years. In 2002, the Food and Drug Administration (FDA) approved the use of low level laser therapy for use in the United States.
How Low Level Laser Therapy is Used 
Low level laser therapy has almost endless applications because of its approach to healing. Its low intensity does not burn or cut tissue like high-powered surgical lasers and there are no known side effects in its over 40 year history of use. Laser therapy is effective in treating many conditions that are prominent today, such as chronic arthritis, tendonitis, carpal tunnel syndrome, fibromyalgia, and sports injuries just to name a few. Many professional athletes utilize laser therapy to reduce healing time to get them back into the game with less chance of re-injury. Countless other people are reaping the benefits of laser therapy by eliminating their dependence on pain medications, avoiding surgery, decreasing or eliminating pain, and returning to a healthier lifestyle.
Conclusion
So, if you think LLLT may help you to cut back or eliminate certain pain medications or avoid surgery, talk to your doctor or health care practitioner. Low level laser therapy has been effective in my practice and is a treatment of choice in providing safe, effective, lasting results for those looking for a better approach to health.
References 
1. Gur A, Karakoc M, Nas K, Cevik R, Sarac J, Demir E. Efficacy of low power laser therapy in fibromyalgia: a single-blind, placebo-controlled trial. Lasers in Medical Science (2002) 17(1):57-61.
2. Oezdemir F, Birtane M, Kokino S. The clinical efficacy of low-power laser therapy on pain and function in cervical osteoarthritis. Clinical Rheumatology (2001) 20(3): 181-184.
3. Simunovic Z, Ivankovich AD, Depolo A. Wound healing of animal and human body sport and traffic accident injuries using low-level therapy treatment; a randomized clinical study of seventy-four patients with control group. Journal of Clinical Laser Medicine and Surgery (2000) Apr;18(2):67-73.
For further information please visit www.theralase.com or call 1-866-843-5273

Tuesday, August 23, 2011

Florida Chiropractic National Convention – 2 Must See Programs on August 25th

August 25th 1:00pm-2:40pm _______________                  Manatee Spring II
John Lockenour, DC, DABCO
Cold Laser Therapy: Clinical and Theory Applications (Clinical CE)
Course Description
This lecture provides an overview on the use of laser therapy in clinical practice. The seminar material covers theories on how lasers work, the effects of laser on living tissue, and the use of lasers in treating specific neuromuscular conditions. Attendees will be introduced to the biophysics and technology of lasers and educated on the practical applications of cold laser therapy in clinical practice, including the treatment of chronic and acute musculoskeletal injuries.
Learning Objectives
• Identify musculoskeletal injury types that are indicated for laser treatments as a primary or adjunctive form of treatment.
• Design laser treatment programs, including frequency of treatments, duration of care, and best ways to target injured areas for musculoskeletal injuries in clinical practice.
• Select optimal laser dosage, including power and time settings, to treat a variety of musculoskeletal conditions in a clinical setting.
• Address frequently asked patient questions about laser by understanding the basic physics and technology.

(Speaker provided by Theralase, Inc.)
3:20pm – 5pm _______________                                                    Orlando LMN
John Lockenour, DC, DABCO
Documenting Your Plan of Care and Its Efficacy (DOC)
Course Description
Plans of Care deficiencies were the major documentation errors found by Medicare's Office of Inspector General when reviewing chiropractic records. Dr. Lockenour will focus on not only meeting the minimum Medicare requirements in documenting your plan of care, but, will explore how doing so will substantiate the medical necessity of care, regardless of third party payer.
Learning Objectives
• Recall the minimum components of documenting a plan of care according to the Medicare LCD for chiropractors
• Relate the importance of addressing and updating the plan of care at each visit.
• Correlate the plan of care to the subjective, objective and assessment findings. 


Come see us at Booth #911

Monday, August 22, 2011

Contra-indications of Therapeutic Laser Treatment


L. Navratil, M. D. J. Kymplova, M. D. Institute of Biophysics, 1st Medical Faculty of the Charles´ University, Prague, CZ leos.navratil@lf1.cuni.cz, jaroslava.kymplova@lf1.cuni.cz
Many contra-indications of non-invasive laser therapy are still surviving in literature. However, some of them are just being mentioned quite uselessly, their justification having never been acknowledged, and their persistant mentioning being based on quoting from one publication to another without authors having examined their validity. Thus numerous useless errors can always appear, and many therapists, whose practical training may have not been primarily aimed at initial use of therapy lasers in medicine, do not only avoid indication of this kind of therapy, but, moreover, they sometimes even discourage their patients despite of the fact that application of therapeutic laser would be a benefit for them in their particular complaint. Contra-indications stated so far can be divided in three main groups: - indications not suitable for laser therapy in general - indications not suitable for laser therapy in some cases - indications stated by mistake as not suitable for laser therapy Indications Not Suitable for Laser Therapy in General It is beyond dispute that laser therapy is contra-indicated on malignant diseases with regard to experimentally proven biostimulative effect, which is brought about by activization of enzymes of respiratory chain (flavin dehydrogenasis, cytochromeoxidasis) with anti-oxidation effect being strengthened simultaneously. The process of tissue oxidation is a chain of reactions, during which electrones in mitochondrias are transferred by a system of carriers from a suitable substrate up to oxygen. Transfer of hydrogen to flavoprotein is connected with production of ATP and ADP, and further transfer through flavoproteinocytochrome system gives life to two more molecules of ATP in each pair of transferred protons. Such a linkage of ATP formation to oxidation is called aerobic phosphorylation. The process is dependent on sufficient supply of ADP and therefore it is under control of a certain kind of a feedback: the quicker the utilization of ATP in tissue, the quicker the production of ADP can be followed and thus the quicker the aerobic phosphorylation there is. This increases concentration of adesinphosphate adesindiphosphate, and adesinmonophosphate in cells after irradiation with therapeutic laser, as described by Romanov et al. Increased amount of energy stimulates quicker replication of mitochondrial DNA in the course of the G0 - S phasis. Locally increased consumptions of oxygen and glucoses prove metabolism in irradiated tissue. Irradiation in the area of neck of patients suffering from hyperthyroidism cannot be recommended, too, due to biostimulation effect. Even though no scientific work describing the influence of therapeutic laser on activity of thyroid gland has been known to us, above mentioned actions can obviously cause this state and therefore it is necessary to carry out applications on this particular area with maximum care. Epilepsy can also be regarded to by some authors as to a significant contra-indication of non- invasive laser therapy. Although the cause of a possible induction of an attack has not been quite clear so far, it is expected that possible cause can be induced by a certain frequency modulation of laser beam.
Direct irradiation of eye retina is a generally accepted contra-indication. Applications of therapeutic laser shall also avoid irradiation of belly of pregnant women, as well as intravaginal applications on them, in spite of Cheeteman and his colleagues having noticed no teratogenous changes on chicken embryae even after irradiations with significantly higher energy density than usually applied. Before we start treatment with a therapeutic laser it is also necessary to confirm that no medication, massage liquid, nor cosmetics, containing a photosensibilitative matter, has been taken by the patient or used on him/her. Should this be the case, there could be a danger of a massive injure of the tissue containing this matter by energy of photons. Indications Not Suitable for Laser Therapy in Some Cases Some authors consider the use of therapeutic lasers contra-indicated for feverish disorders and infectious diseases. It is always necessary to judge the particular state of health and etiology of a disease. Discrepancies in data evaluating the effect of therapeutic laser on activity of bacteria and/or viruses should be stressed. Some scientific works point at direct sensitivity of some microorganisms on therapeutic laser. Such sensitivity can be utilized especially in dentistry as it can be seen on decreased vitality of microflora after irradiation of mucosis in mouth (bacteriostatic effect of laser). G+ bacterias are especially sensitive. This presumption has been proven even in laboratory conditions, where upon irradiation of the cultivation plate with energy density of 2 Joules per disc, decreased growth of almost all common varieties of pathogenic bacteria could be noticed. On the other hand, some papers describe a positive biostimulation effect of laser on growth of bacteria. For example, highest stimulation of growth with energy density 337.0 mJ/cm2 has been reported with a GaAs laser, however other papers do not mention growth stimulation of bacteria with a therapeutic density of energy. Also here a dependency of biostimulation effect of laser irradiation on wavelength of laser can be seen, where, on one hand, rays of Ruby and Neodymium lasers do not stimulate growth of grammpositive bacteria, whilst on the other hand Ruby laser increases production of pigment in Pseudomonas Aeruginosa. Studies from the Medical Faculty of Palacky´s University in Olomouc, CZ, have followed dependency of length of laser expozition on growth of microbes, both on blood agar on cultivation plate and in broth. Tribes of Staphylococcus Aureus, Streptococcus b Haemolyticus, Streptococcus Pneumoniae and Neisseria Catarrhalis were used for the experiment. With these tribes being applied on agar soil in quantity of 104 microbes /1 ml, no macroscopically visible changes could be noticed in comparison with the control group after irradiation of the plate by a He-Ne laser with energy density of 0.3, 0.6, 1.5, 3.0 and 6.0 J/cm2 . In the second case the tribes were irradiated in broth twice in 2 hours interval, each with the energy of 6 J per 5 ml of broth. In all used bacterial tribes higher activity of irradiated cultures in comparison with control groups could be registered. However, more significant activity, in higher orders, has only been registered with Staphyllococcae. Thus these results would rather confirm the fact that no direct antibacterial effect does contribute to the processes of healing. Positive effect of laser irradiation in purulent wounds and trophic ulcers can therefore be caused by improvement of local immunity of irradiated tissue, by activation of phagocytosis and proteolytic ferments, as well as by increased blood flow. These studies clearly identify necessity of individual access with no useless apprehension towards each patient with above mentioned complaints. The authors can see no particular reason for avoiding non-invasive laser therapy if the source of infection is not directly irradiated. Application of laser will speed up initial healing of such an open wound (ulcus cruris, bed sores etc.).
Neither it is possible to mention blood diseases as contra-indications of therapeutic laser. The issue is just too broad, for with a little hyperbole, a slight hypochromatic anemia as well as a myeloblastic leucaemia, imminently endangering life, can both be considered blood diseases. Whilst for the use of therapeutic laser on patients suffering from malignant haematological disorders the rules mentioned above in this work must be observed, it is unnecessary to avoid this kind of treatment in case of anemia, caused by iron insufficiency as a result of one-sided food. Several years of our experience have clearly proven that initial laser therapy has no influence on lifetime of blood cells and we can see no reason why to avoid application of laser in any area with the exception of irradiation of localities with blood-productive marrow. Due care is necessary when using therapeutic laser on patients with a higher blood loss, with regard to vasodilatation effect of laser therapy. Analgesic effect of non-invasive laser therapy is brought, among others, by decreased sensitivity of peripheral neural terminations. That is why maximum care should be taken in the course of applications of therapeutic laser in areas with lower sensitivity, where a combination of these two phenomena can disqualify local natural protective mechanism of the body and increased jeopardy of damage in affected area, for example by sunshine, can be a real threat. Indications Stated by Mistake as Not Suitable for Laser Therapy Other contra-indications mentioned in literature from time to time can be considered, from the point of view of contemporary level of knowledge on laser therapy, useless and confusing for doctors. Here we have in mind especially the use of therapeutic laser on patients with a pacemaker. Should this contra-indication be right, it would also mean contra-indication of x-ray examination or of direct exposure to sunlight on skin for these people. As far as we know, this contra-indication came to literature by mistake, and through references to and by various authors this error is still preserved. Application of therapeutic laser in the area of gonads one does not have to be afraid of, it is only necessary to keep to recommended amounts of energy. With lower power density (up to 1.3 J/cm2) laser has a stimulative effect on male germina cells, however with several times multiplied energy density a possibility of mutation cannot be fully cut out. No negative effect of non-invasive laser therapy has been reported on women, even when applied intravaginally. Further questionable contra-indications are states of exhaustion or decrepitude, or dependency on alcohol and/or drugs, frequently given in literature. These contra-indications cannot be considered logical. On the contrary, local applications of therapeutic laser in some indications mean significant contribution for patients, and such a therapy is, with regard to its minimal side-effects, definitely more considerate for them in comparison with any other kind of treatment (for example with medication). Works of English authors have proven that apprehensions of possible damage to epiphyseal fissures in case of application of laser therapy in this area are useless. In the light of works of the authors from Motol we can brand useless gratuitous apprehensions of application of therapeutic laser on patients with worse express or seize abilities resulting from damage of cerebral tissue. However, it is necessary to stress that in this case laser should be in hands of well experienced specialist. Conclusions:
The authors of this work are well aware of the fact that the cogent issue has only been denoted here. However, the extent of the paper cannot be widened with regard to technical capacities of the publisher, and therefore they refer to further professional literature by theirs, or by other authors.

Thursday, August 18, 2011

Theralase to Present Ground Breaking Scientific Study Results at Two International Conferences


Toronto, ON – August 18, 2011 - Theralase Technologies Inc. (TSXV: TLT) announced today that it is presenting preclinical study results at two international scientific conferences.

At the first conference, the preclinical study will document the rapid detection of microorganisms, such as bacteria. At the second conference the preclinical study will explain how the proprietary Theralase technology activates the key inducible Nitric Oxide Synthase (iNOS) pathway. Dr. Lothar Lilge, a Professor in the Department of Medical Biophysics; University of Toronto will be delivering both presentations. These exciting studies highlight Theralase’s commitment to advancing its exclusive patented technologies, which could lead to significant commercial advantages for the company.

The first conference will be held from August 17 to19, 2011 in Puebla, Mexico. Dr. Lilge will present at the International Commission on Optics on a "Technique for Rapid Microorganism Detection" developed as a partial result of Theralase's research and development of Theralase's patented Photo Dynamic Compounds (PDC) for the inactivation and destruction of microorganisms, such as bacteria. Photo Dynamic Compounds are light sensitive super molecules able to destroy cancerous cells, bacteria and viruses when light activated by Theralase’s proprietary laser sources. The technique presented provides an opportunity for Theralase to augment its PDC inactivation research and development program with the means for the rapid detection of various types of bacteria in approximately 1 hour versus the current standards requiring typically 1 to 2 days.

At the second conference, Dr. Lilge will present at the North American Association of Laser Therapy (NAALT) at their 2011 Conference in Milwaukee, Wisconsin from September 22 to 24, 2011. The preclinical study by Theralase pertains to the mechanism of action of its 660 nm and 905 nm dual wavelength low level laser therapy (LLLT) and further explains how the proprietary Theralase technology activates the key inducible Nitric Oxide Synthase (iNOS) pathway. The research goes into detail to explain the importance of the iNOS pathway for accelerating the healing of tissue and why the Theralase dual wavelength technology is able to completely activate this key cellular pathway.

About Theralase Technologies Inc.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com or www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.


For More Information
Roger Dumoulin-White                                                                      
President & CEO,                              
416-447-8455 ext. 225                                   
rwhite@theralase.com                                   
                                               

Greg Bewsh
Director of Investor Relations,
416-447-8455 ext. 262

Tuesday, August 16, 2011

How Does Cold Laser Therapy Work?


OK, forget about the popularized depictions of lasers as light sabres and alien death rays. In the therapeutic context, a laser is simply a source of electromagnetic energy that is monochromatic – providing a consistent wavelength that travels in the same direction.
Until recently, most medical lasers have been thermal or ‘hot’, in that they are capable of deeply penetrating and heating body tissue -- thus cutting, cauterizing or destroying it. Thermal lasers, such as those used in surgery, typically operate at power levels in excess of 25,000 mW.
Non-thermal, or “cold” lasers, are also capable of penetrating into human tissue, but do not heat the tissue sufficiently to cause damage. Non-thermal lasers, such as those indicated for Low Level Laser Therapy (LLLT) typically operate at power levels between 10 mW and 500 mW and are totally painless. They are a delivery mechanism for electromagnetic energy (at a specific wavelength within the infrared range of the electromagnetic spectrum) which triggers the cellular metabolic cascade discussed later.
A HISTORY OF LOW LEVEL LASER THERAPY (LLLT)
In the late 1960's, scientists in Europe began to research the use of very low powered lasers (less than 5 mW) to produce non-thermal effects, or ‘biostimulation,’ in human tissue. The first experimental applications of LLLT were reported in 1968, when researchers used ruby and argon lasers on non-healing or slow-to-heal ulcers. Later research substantiated the efficacy of LLLT to accelerate the healing of wounds, attenuate pain, and reduce tissue inflammation in both humans and animals. During the 1980’s, the use of more highly-powered lasers was investigated, though power levels were still very low by today’s standards. Power levels in LLLT devices today range from 50 mW (very low power) up to 500 mW (high power).
 In the past ten years, LLLT technology has advanced significantly for three key reasons:
Extensive research has been conducted at leading academic and medical institutions around the world concerning the basic underlying science of how LLLT affects mammalian tissue. For example: At the annual meeting of the American Society for Laser Medicine and Surgery in April, 2003, teams from the U.S., Canada, England, Ireland, Russia, China, Italy, Iran and Egypt presented papers on topics ranging from the effect of laser light on fibroblasts and the rheological properties of red blood cells, to the effects of LLLT on pressure ulcers, tibia fractures and snake bites. Even the U.S. Department of Defense has funded research at the Uniformed Services University in Maryland into the use of LLLT to treat wounded soldiers.
The number of sophisticated (i.e., prospective, double-blind, randomized, placebo-controlled) clinical trials for LLLT has increased substantially. Clinical trials over the last several years have ranged from the study of LLLT to treat pain associated with carpal tunnel syndrome and soft tissue injuries to dermatological and dental applications. The quality of data collected from these clinical trials has significantly improved.
In January, 2002, the FDA changed the device classification on LLLT devices to be classified as a “non-significant risk”, greatly streamlining the FDA clearance process. As a result, the number of LLLT devices cleared for the treatment of various medical conditions has increased dramatically.
HOW LLLT WORKS
The effects of exposing human and animal tissue to low level laser light in the infrared range appear to be photochemical, in that it initiates a chain of chemical reactions similar to photosynthesis in plant cells. In LLLT, light energy is received within the cell mitochondria and at the cell membrane by specific chromophore receptors, initiating the conversion of light energy into metabolic cellular energy through a process called photobiostimulation.
 In mammal tissue, photobiostimulation results in an apparent increase in the cellular metabolic rate and stimulation of the immune, lymphatic and vascular systems -- all of which expedite cell repair. The net result, as observed in clinical trials to date, is a reduction in pain, inflammation, edema and an overall reduction in healing time. The sooner LLLT is applied to the affected area, the faster results appear to be achieved. Also, the effects of LLLT have been proven to be greater in compromised or damaged cells. Exactly how LLLT effects mammal tissue is still a subject of considerable investigation within the scientific community. But with an ever-increasing number of peer-reviewed papers published, the basic metabolic pathways and mechanism of action of LLLT are becoming well understood. In laboratory research and clinical applications, LLLT has produced the following physiological effects:
Intracellular chromophores (including endogenous porphyrins, mitochondrial and membranal cytochromes, and flavoproteins – which are all photosensitizers) absorb electromagnetic radiation in the IR range and transfer it to nearby oxygen molecules, thus producing reactive oxygen species (ROS) and antioxidants. At very low concentrations, ROS have strong stimulatory effects on cellular metabolic pathways.
·         Stimulates ATP production within mitochondria, elevating overall cellular metabolism.
·         Increases RNA and DNA synthesis, which promotes cell proliferation. This helps damaged cells be replaced more promptly, which reduces healing time.
·         Stimulates Superoxide Dysmutase (“SOD”) production. SOD is an enzyme that breaks down free radicals, which can be a cause of muscle pain.
·         Increases vascularity by increasing the formation of new capillaries and repairing damaged ones. The resulting increase in blood circulation promotes localized healing.
·         Stimulates cell proliferation and motility (ability to move under their own power).
·         Stimulates fibroblast formation. Fibroblasts are present in connective tissue and give rise to precursor cells, which form the fibrous, binding and supporting tissues like collagen and glycoprotein.
·         Stimulates the production of collagen, which is the most common protein found in the body. It is essential for the repair of damaged tissue and for replacing old tissue. Collagen is the substance that holds cells together, in particular the fibres of tendons, ligaments and the fascia. Also, by increasing collagen production less scar tissue is formed at the damaged site.
·         Stimulates tissue granulation and connective tissue projects, which are part of the healing process of wounds, ulcers or inflamed tissue.
·         Stimulates leukocyte production. Leukocytes, or white blood cells, are involved in defending the body against infective organisms and foreign substances.
·         Stimulates macrophages and phagocytosis. Macrophages are large white blood cells that engulf and destroy (phagocytosis) microorganisms, cellular debris and other foreign matter. Macrophages are involved in cell-mediated immune responses. They are drawn to inflamed areas and are particularly important in the body’s defense against infection.
·         Stimulates the release of endorphins, enkephalins, and dynorphins - which are the body’s natural pain fighting chemicals.
·         Reduces the excitability of nervous tissue, thus reducing the sensory transmission of pain.
·         Accelerates lymphatic system activity. Edema, which is the swelling process of the body, has two basic components. The first component is liquid, which can be evacuated by the cardiovascular system. The second is comprised of proteins, which have to be evacuated by the lymphatic system. Research has shown that the lymph vessel diameter and the flow of the lymph system can be doubled with the use of low-level laser therapy. The venous diameter and the arterial diameters can also be increased. This means that both edema components (liquid and protein) can be evacuated at a much faster rate - to relieve inflammation.
·         Inhibits prostaglandins’ physiological effects on tissue, which effects vasodilation, edema, and stimulated intestinal and bronchial smooth muscle.
·         Stimulates serotonin release. Serotonin is an endorphin precursor, and is also associated with the relief and resolution of inflammation. The net result of properly administered LLLT can be significant reductions in pain and inflammation accompanied by accelerated healing times.
LLLT EXAMPLE: ACUTE SOFT TISSUE TRAUMA
An injury of this type consists of damage to muscular, neural, lymphatic and vascular tissue. The body's natural reaction to acute soft tissue trauma is to "splint" the injury with edema, an accumulation of thin or watery fluid in tissue spaces or cell interstices, which causes swelling. This swelling prevents excessive movement of the damaged tissue and results in trauma pain from the injured tissue, as well as secondary pain from the swelling itself. In such instances, LLLT has been shown to improve the efficiency of the lymphatic system, thereby correcting the fluid balance in the body and reducing edema and improving range of movement. LLLT has also been shown to decrease the transmission of pain by C-fiber nerves, and increase overall cellular metabolism, so cells replicate and heal at a much faster rate.
 LLLT can be used in conjunction with the majority of traditional medicines, including narcotics, opiates, anticonvulsants and antidepressants; however, cortisone steroids may negate LLLT’s immune enhancement. LLLT can also be used in conjunction with other forms of energy therapy such as ultrasound, TENS therapy and electrical stimulation.
LLLT EXAMPLE: TREATMENT OF CHRONIC PAIN
Chronic pain is typically defined as pain that continues for a month or more beyond the usual recovery period for an illness or injury, or pain that occurs for months or years due to a chronic medical condition. Examples include pain resulting from cancer or cancer therapy, pre-operative pain (pain induced by invasive surgical procedures) and pain associated with arthritis and fibromyalgia.
 Traditional methods for pain management include over-the-counter and prescription medications, physical therapy, TENS therapy (the application of electrical impulses to the skin), psychological therapy and nerve blocking (injections that provide temporary relief). More aggressive options include neuromodulation (the implantation of devices that utilize electrical impulses to control chronic pain), implantable drug pumps and alternative therapies such as acupuncture. LLLT has the potential to replace many of these therapies for the treatment of pain, particularly chronic and acute spine and joint pain, for several reasons:
 Safety - Many current therapies for the treatment of chronic pain have a number of significant drawbacks. For example, the negative impact of long-term non-steroidal anti-inflammatory, narcotics and opiate use on the gastrointestinal and nervous systems has been highly documented. The implantation of pain management devices such as neuromodulators and drug pumps is accompanied by even greater risks, including infection, bleeding and an adverse reaction to anaesthesia. LLLT technology, on the other hand, can be safely applied to most regions of the body, including directly over the spinal vertebrae and over orthopaedic hardware or stimulators that have been surgically implanted. Ultrasound and high-level electrical stimulation, in comparison, are contraindicated for clinical applications directly over the spine. Ultrasound is also contraindicated for use over orthopaedic hardware. In fact, the primary adverse effects associated with LLLT are minor, and include redness and skin irritation.
 Comfort – LLLT is a non-invasive procedure, and minimal pain has been documented from its use. This is not the case with more aggressive options such as TENS therapy, nerve blocking injections, and the implantation of drug pumps and neuromodulators.
 Efficacy – LLLT has been shown to improve chronic pain to a statistically significant degree in just twelve sessions lasting 10 to 30 minutes each. In an early IRB-sponsored study performed by Therapeutic Laser Associates on 20 patients who had undergone spinal fusion using bone harvested from the iliac crest, the mean improvement in donor site pain for patients undergoing at least eight sessions of LLLT was 50.1%. The mean improvement in donor site pain during the last 24 hours of LLLT treatment was 47.0%, some improvement in donor site pain was noted in 80.0% of patients, and 65% of patients had pain reduction of 50% or more. Equally as important as pain relief, however, is the ability of LLLT to enable critical medical intervention in high-risk situations. For example, many skeletal injuries result in massive edema that can hinder a surgeon’s ability to repair the fracture. In certain situations, delaying surgery can result in severe loss of limb function, and may even result in a medical condition that requires amputation. In these instances, LLLT has been demonstrated to reduce edema sufficiently so that corrective surgery can occur in a timely manner.
For more information please call 1-866-843-5273 or visit www.theralase.com

Tuesday, August 2, 2011

What Your Patients Can Expect From Laser Therapy (and Grow Your Practice)

What To Expect

The treatment is non-invasive and pain-free. After a few applications of laser therapy one can expect:
  • Reduction in pain 
  • Better mobility and range of motion
  • Reduction in the use of pain medication including cortisone
  • Improvement of well being (better sleep and mood, more energetic, etc.)

Chronic Pain Management

You don't need to live with pain. Millions of Canadians suffer from chronic pain, and many are seeking alternative treatment methodologies to overused prescription medications that are now clinically proven to have significant side effects.
Low level laser is a non-invasive, non-toxic treatment methodology that is effective for numerous types of acute and chronic pain. The HealthPoint Laser system works by delivering billions of photons to the tissue surface driving this energy down to the damaged cells that require this energy for healing.  Our Theralase® superpulsed laser is able to drive light energy up to 4” below the skin surface. Light energy of the correct wavelength (color) and power is able to dramatically increase the healing rate of damaged cells; thus allowing the body to heal itself at an accelerated rate. Pain is believed to originate from an ionic differentiation of potassium and sodium gradient across a cellular membrane. The Theralase® superpulsed laser with its 905nm near infrared technology has been clinically proven to be absorbed by the inter-lipid layer forming the cellular membrane of cells.  The increase in cellular membrane permeability induced by the Theralase® laser system causes a re-absorption of sodium and potassium molecules thus removing the gradient and hence the pain signal.

Anti-Inflammation

Low level laser therapy has an anti-edemic [anti-swelling] effect as it causes vasodilation [dilation of the blood vessels], but also because it activates the lymphatic drainage system.

Anti-Pain (Antalgic)

Due to less inflammation, there is less of an edema and thus less pain. Low level laser therapy stimulates the vasodilation and lymphatic drainage, which increases the re-absorption of pain-causing products. Low level laser therapy regulates the sodium-potassium pump (this pump maintains the potential across the membrane of a nerve cell, which leads to pain transmission signals) and thus removes the transmission of pain signals from this area.

Examples Of Conditions Treated


 Arthritis Tendonitis
 Headaches Whiplash
 Low back and sciatic pain Plantar Fasciitis
 Carpal Tunnel Syndrome Sports injuries
 Tennis and Golfer's Elbow Fibromyalgia
 Post-operative pain Inflammation
 Sprains and strains Migraine headaches
 TMJ Syndrome Bone healing
 Shingles Wound healing
 Knee pain Dental pain
 Neck pain Sinusitis
 Bursitis Raynaud's syndrome